These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 26480701)

  • 1. [Fingolimod].
    Hashi Y; Kondo T
    Nihon Rinsho; 2015 Sep; 73 Suppl 7():205-11. PubMed ID: 26480701
    [No Abstract]   [Full Text] [Related]  

  • 2. Severe rebound after withdrawal of fingolimod treatment in patients with multiple sclerosis.
    Gündüz T; Kürtüncü M; Eraksoy M
    Mult Scler Relat Disord; 2017 Jan; 11():1-3. PubMed ID: 28104247
    [No Abstract]   [Full Text] [Related]  

  • 3. Herpes zoster: a potential risk associated with fingolimod treatment.
    Mayor Ibarguren A; Gómez Fernández C; Tallón Barranco A; Fernández Fournier M; González Ramos J; Romero Gómez MP; Herranz Pinto P
    Int J Dermatol; 2015 Sep; 54(9):e373-5. PubMed ID: 26173466
    [No Abstract]   [Full Text] [Related]  

  • 4. Polydermatomal perineal and gluteal herpes zoster infection in a patient on fingolimod treatment.
    Kawiorski MM; Viedma-Guiard E; Costa-Frossard L; Corral I
    Enferm Infecc Microbiol Clin; 2015 Feb; 33(2):138-9. PubMed ID: 24958672
    [No Abstract]   [Full Text] [Related]  

  • 5. Visceral leishmaniasis infection in a fingolimod-treated multiple sclerosis patient.
    Artemiadis AK; Nikolaou G; Kolokythopoulos D; Tegos N; Terentiou A; Triantafyllou N; Papanastasiou I
    Mult Scler; 2015 May; 21(6):795-6. PubMed ID: 25432949
    [No Abstract]   [Full Text] [Related]  

  • 6. Famous.
    Kim MJ; Bhatti MT; Costello F
    Surv Ophthalmol; 2016; 61(4):512-9. PubMed ID: 26742785
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiple sclerosis treatment with fingolimod: profile of non-cardiologic adverse events.
    Fragoso YD
    Acta Neurol Belg; 2017 Dec; 117(4):821-827. PubMed ID: 28528469
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A pragmatic approach to dealing with fingolimod-related lymphopaenia in Europe.
    Giovannoni G; de Jong B; Derfuss T; Izquierdo G; Mazibrada G; Molyneux P; Nicholas R; Overell J; Ziemssen T; Juliusson G
    Mult Scler Relat Disord; 2015 Jan; 4(1):83-4. PubMed ID: 25787058
    [No Abstract]   [Full Text] [Related]  

  • 9. [Treatment for multiple sclerosis in patients with collagen diseases].
    Kohriyama T; Ochi K
    Nihon Rinsho; 2015 Sep; 73 Suppl 7():234-40. PubMed ID: 26480706
    [No Abstract]   [Full Text] [Related]  

  • 10. Persistent headache in patients with multiple sclerosis starting treatment with fingolimod.
    Fragoso YD; Adoni T; Gomes S; Goncalves MV; Matta AP; Mendes MF; Siquineli F
    Headache; 2015 Apr; 55(4):578-9. PubMed ID: 25754576
    [No Abstract]   [Full Text] [Related]  

  • 11. Cutaneous cryptococcosis in a patient taking fingolimod for multiple sclerosis: Here come the opportunistic infections?
    Carpenter AF; Goodwin SJ; Bornstein PF; Larson AJ; Markus CK
    Mult Scler; 2017 Feb; 23(2):297-299. PubMed ID: 28165320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peripheral blood T cell dynamics predict relapse in multiple sclerosis patients on fingolimod.
    Song ZY; Yamasaki R; Kawano Y; Sato S; Masaki K; Yoshimura S; Matsuse D; Murai H; Matsushita T; Kira J
    PLoS One; 2014; 10(4):e0124923. PubMed ID: 25919001
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term cardiac safety and tolerability of fingolimod in multiple sclerosis: A postmarketing study.
    Paolicelli D; Manni A; Direnzo V; D'Onghia M; Tortorella C; Zoccolella S; Trojano M
    J Clin Pharmacol; 2015 Oct; 55(10):1131-6. PubMed ID: 25903516
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging tumefactive MS after switching therapy from interferon-beta to fingolimod: A case report.
    Harirchian MH; Taalimi A; Siroos B
    Mult Scler Relat Disord; 2015 Sep; 4(5):400-402. PubMed ID: 26346786
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Change in vital signs after fingolimod initiation in patients with multiple sclerosis: the possible need for 24 h monitoring.
    Tomohiko U; Mori M; Akiyuki U; Masuda S; Mutho M; Masuda H; Kuwabara S
    Br J Clin Pharmacol; 2015 Sep; 80(3):607-8. PubMed ID: 26077133
    [No Abstract]   [Full Text] [Related]  

  • 16. Successful treatment of fingolimod-associated macular edema with intravitreal triamcinolone with continued fingolimod use.
    Thoo S; Cugati S; Lee A; Chen C
    Mult Scler; 2015 Feb; 21(2):249-51. PubMed ID: 24696055
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adaptive Immune Responses in a Multiple Sclerosis Patient with Acute Varicella-Zoster Virus Reactivation during Treatment with Fingolimod.
    Harrer A; Wipfler P; Pilz G; Oppermann K; Haschke-Becher E; Afazel S; Kraus J; Trinka E; Sellner J
    Int J Mol Sci; 2015 Sep; 16(9):21832-45. PubMed ID: 26378517
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early relapse with tumefactive MS lesion upon initiation of fingolimod therapy.
    Boangher S; Goffette S; Van Pesch V; Mespouille P
    Acta Neurol Belg; 2016 Mar; 116(1):95-7. PubMed ID: 26071761
    [No Abstract]   [Full Text] [Related]  

  • 19. Retinal hemorrhages following fingolimod treatment for multiple sclerosis; a case report.
    Ueda N; Saida K
    BMC Ophthalmol; 2015 Oct; 15():135. PubMed ID: 26481728
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fingolimod induces BAFF and expands circulating transitional B cells without activating memory B cells and plasma cells in multiple sclerosis.
    Miyazaki Y; Niino M; Takahashi E; Suzuki M; Mizuno M; Hisahara S; Fukazawa T; Amino I; Nakano F; Nakamura M; Akimoto S; Minami N; Fujiki N; Doi S; Shimohama S; Terayama Y; Kikuchi S
    Clin Immunol; 2018 Feb; 187():95-101. PubMed ID: 29079163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.